Abstract
Background The incidence of benign prostatic hyperplasia peaks 80% in old age. Bothersome symptoms and progression to acute urinary retention and need for surgery are important concerns. Apha blockers and 5 alpha reductase inhibitors address these to variable extents. This article reviews the current place of medical therapy in the treatment of BPH, with a focus on combination therapy. Data Source A medline literature search was performed to identify original studies including global multi-center trials and reviews on the subject. Conclusion BPH symptom reduction and shrinkage of prostate size by the use of a combination of alpha adrenergic uroselective blocker (Tamsulosin) and 5 alpha iso-enzyme inhibitor (Dutasteride) is a first option of therapy in the management of BPH especially in those cases that are surgical risks with the category of mild to moderate prostate symptom scores. The Annals of African Surgery, Volume 6, 2010
Highlights
Benign prostatic hyperplasia (BPH) is the most common cause of urinary bladder outflow obstruction (BOO) in men aged 50 years and above[1]
The progression of BPH and worsening of symptoms results in acute retention of urine (AUR) and demand for BPH related surgery [7]
Two factors reported to predict the progression to AUR include prostatic volume >30cc and serum prostatic specific antigen >1.5ng/ml and
Summary
The incidence of benign prostatic hyperplasia peaks 80% in old age. Bothersome symptoms and progression to acute urinary retention and need for surgery are important concerns. Data Source A medline literature search was performed to identify original studies including global multi-center trials and reviews on the subject
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
